Processa Pharmaceuticals, Inc. (PCSA) Return on equity 2021–2022
Processa Pharmaceuticals, Inc. (PCSA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-367.1%FY2022 · since FY2021: -44.8% → -367.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -367.1% | -322.2 pp |
| FY2021 | -44.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More PCSA financial trends
PCSA RevenuePCSA Net incomePCSA Net marginPCSA Gross profitPCSA Gross marginPCSA Operating incomePCSA Operating marginPCSA Operating cash flowPCSA Free cash flowPCSA Capital expendituresPCSA Stock buybacksPCSA Dividends paidPCSA Total assetsPCSA Total liabilitiesPCSA Shareholders’ equityPCSA overview →